BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D’Aiuto M, Petrillo A, Lastoria S, Siani C, Comella G. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009;20:1185-1192. [PMID: 19218307 DOI: 10.1093/annonc/mdn748] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 2020;17:E2078. [PMID: 32245065 DOI: 10.3390/ijerph17062078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
4 Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J 2012;18:41-51. [PMID: 22098334 DOI: 10.1111/j.1524-4741.2011.01175.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
5 Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol 2015;95:88-104. [PMID: 25900915 DOI: 10.1016/j.critrevonc.2015.02.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
6 Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y, Wang Y, Zhang J, Wu Z, Lu J. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget 2017;8:79305-14. [PMID: 29108309 DOI: 10.18632/oncotarget.17954] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Dizdar O, Altundag K. Current and emerging treatment options in triple-negative breast cancer. Oncol Rev 2010;4:5-13. [DOI: 10.1007/s12156-009-0031-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr 2010;160:174-81. [PMID: 20473728 DOI: 10.1007/s10354-010-0773-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
9 Xu Y, Lin Y, Wang Y, Zhou L, Xu S, Wu Y, Peng J, Zhang J, Yin W, Lu J. Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine 2021;38:101031. [PMID: 34337367 DOI: 10.1016/j.eclinm.2021.101031] [Reference Citation Analysis]
10 Li H, Bergeron S, Annis MG, Siegel PM, Juncker D. Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray. Mol Cell Proteomics 2015;14:1024-37. [PMID: 25680959 DOI: 10.1074/mcp.M114.046516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
12 Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106-116. [PMID: 26175926 DOI: 10.7497/j.issn.2095-3941.2015.0030] [Cited by in F6Publishing: 147] [Reference Citation Analysis]
13 Frasci G, D’aiuto G, Comella P, D’aiuto M, Di Bonito M, Ruffolo P, Iodice G, Petrillo A, Lastoria S, Oliviero P, Capasso I, Montella M, Siani C, Santangelo M, Vizioli L, Comella G. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Annals of Oncology 2010;21:707-16. [DOI: 10.1093/annonc/mdp356] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
14 Hurley J, Reis IM, Rodgers SE, Gomez-fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013;138:783-94. [DOI: 10.1007/s10549-013-2497-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
15 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. Oncol Lett 2015;9:2825-32. [PMID: 26137155 DOI: 10.3892/ol.2015.3072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084-2090. [PMID: 21737257 DOI: 10.1016/j.ejca.2011.06.014] [Cited by in Crossref: 152] [Cited by in F6Publishing: 133] [Article Influence: 15.2] [Reference Citation Analysis]
17 Chen X, Nie X, Chen C, Wu J, Wu J, Lu J, Shao Z, Shen Z, Shen K. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Annals of Oncology 2010;21:961-7. [DOI: 10.1093/annonc/mdq041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
18 Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci 2013;33:262-5. [PMID: 23592141 DOI: 10.1007/s11596-013-1108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
20 Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current Opinion in Oncology 2011;23:566-77. [DOI: 10.1097/cco.0b013e32834bf8ae] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
21 Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol 2013;139:905-14. [PMID: 23440492 DOI: 10.1007/s00432-013-1399-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Gelmon K, Dent R, Mackey J, Laing K, Mcleod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of Oncology 2012;23:2223-34. [DOI: 10.1093/annonc/mds067] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 12.4] [Reference Citation Analysis]
23 Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011;18:165-73. [PMID: 21290263 DOI: 10.1007/s12282-011-0254-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
24 Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M. A tripla-negatív emlőkarcinóma – irodalmi áttekintés. Magyar Onkológia 2010;54:325-35. [DOI: 10.1556/monkol.54.2010.4.6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015;3:257-75. [PMID: 26676166 DOI: 10.1016/j.bbacli.2015.03.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 30.7] [Reference Citation Analysis]
26 Chen Y, Guan Y, Wang J, Ma F, Luo Y, Chen S, Zhang P, Li Q, Cai R, Li Q, Mo H, Lan B, Chen X, Zhao W, Xu B, Fan Y. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Int J Cancer 2020;147:3490-9. [PMID: 32588429 DOI: 10.1002/ijc.33175] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 O'toole SA, Beith JM, Millar EKA, West R, Mclean A, Cazet A, Swarbrick A, Oakes SR. Therapeutic targets in triple negative breast cancer. J Clin Pathol 2013;66:530-42. [DOI: 10.1136/jclinpath-2012-201361] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
28 Nanda R. “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. Seminars in Oncology 2011;38:254-62. [DOI: 10.1053/j.seminoncol.2011.01.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
29 Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013;24:1219-25. [PMID: 23223332 DOI: 10.1093/annonc/mds603] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
30 Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009;20:1913-1927. [PMID: 19901010 DOI: 10.1093/annonc/mdp492] [Cited by in Crossref: 357] [Cited by in F6Publishing: 326] [Article Influence: 29.8] [Reference Citation Analysis]
31 Aakko S, Straume AH, Birkeland EE, Chen P, Qiao X, 'Lønning PE, Kallio MJ. MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells. Transl Oncol 2019;12:170-9. [PMID: 30359947 DOI: 10.1016/j.tranon.2018.10.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
32 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 2014;9:1-11. [PMID: 24476748 DOI: 10.2147/CE.S52197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
33 Takeda R, Naka A, Ogane N, Kameda Y, Kawachi K, Shimizu S, Kamoshida S. Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer. Breast Cancer (Auckl) 2015;9:49-57. [PMID: 26309405 DOI: 10.4137/BCBCR.S27534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
35 Telli ML, Ford JM. Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer 2010;10 Suppl 1:E16-22. [PMID: 20587403 DOI: 10.3816/CBC.2010.s.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
36 Kim H, Jung K, Im S, Im Y, Kang S, Park K, Lee S, Kim S, Lee K, Ahn J, Kim S, Sohn J. Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Annals of Oncology 2013;24:1485-90. [DOI: 10.1093/annonc/mds658] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
37 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
38 Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. Bull Cancer 2013;100:453-64. [PMID: 23695030 DOI: 10.1684/bdc.2013.1740] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
39 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014;144:223-32. [PMID: 24557340 DOI: 10.1007/s10549-014-2876-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 11.6] [Reference Citation Analysis]
40 Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L, Di Leo A. Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast 2011;20:S135-41. [DOI: 10.1016/s0960-9776(11)70311-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
41 Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res 2020;26:2838-48. [PMID: 32046998 DOI: 10.1158/1078-0432.CCR-19-3492] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 60.0] [Reference Citation Analysis]
42 Cleere DW. Triple-negative breast cancer: a clinical update. Community Oncology 2010;7:203-11. [DOI: 10.1016/s1548-5315(11)70394-1] [Cited by in Crossref: 25] [Article Influence: 2.3] [Reference Citation Analysis]
43 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
44 Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL, Wang W. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109:1876-1885. [PMID: 24008666 DOI: 10.1038/bjc.2013.534] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 12.4] [Reference Citation Analysis]
45 Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr. 2011;2011:108-110. [PMID: 22043054 DOI: 10.1093/jncimonographs/lgr038] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
46 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
47 Yang W, Ahmed M, Elian M, Hady el-SA, Levchenko TS, Sawant RR, Signoretti S, Collins M, Torchilin VP, Goldberg SN. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology 2010;257:685-96. [PMID: 20858851 DOI: 10.1148/radiol.10100500] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
48 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wu X, Tang P, Li S, Wang S, Liang Y, Zhong L, Ren L, Zhang T, Zhang Y. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun 2018;9:832. [PMID: 29483583 DOI: 10.1038/s41467-018-03210-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
50 Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin Ther Targets 2014;18:863-81. [PMID: 24798880 DOI: 10.1517/14728222.2014.915315] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
51 Engel JB, Martens T, Hahne JC, Häusler SF, Krockenberger M, Segerer S, Djakovic A, Meyer S, Dietl J, Wischhusen J, Honig A. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anti-Cancer Drugs 2012;23:426-36. [DOI: 10.1097/cad.0b013e32834fb8ce] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
52 Greil R. The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management. Breast Care (Basel) 2009;4:144-7. [PMID: 20847873 DOI: 10.1159/000225388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]